Mon, Jul 14, 2014, 12:37 PM EDT - U.S. Markets close in 3 hrs 23 mins

Recent

% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

neii 5 posts  |  Last Activity: Jun 16, 2014 9:32 AM Member since: Mar 20, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • eoStem presents results for Phase 1 study of autologous Treg immunotherapy
    NeoStem announced the presentation of the results of an open-label dose escalation Phase 1 clinical study of autologous T regulatory cell, or Treg, immunotherapy for type 1 diabetes mellitus, or T1DM, indicating safety and tolerability following administration. As reported by UCSF, in the study, 14 patients between 18 and 45 years of age with a mean duration of disease of 10 months all of whom retained a baseline level of insulin production, received a single infusion of autologous Tregs expanded ~500-fold. The infusions were well tolerated; the majority of adverse events reported were mild. Infused Tregs peaked in circulation 3-7 days after infusion and were detectable at greater than 6 months. The average levels of stimulated C-peptide, an indicator of pancreatic islets beta cell function, for some patients remained stable from baseline for as long as 2 years post treatment. These data suggest that the treatment was safe and did not adversely affect residual beta cell function. The Tregs were observed to be highly functional and long lived in treated individuals. While the U.S. Phase 1 study was designed to evaluate safety and tolerability in adults who have suffered T1DM for various durations, supportive evidence of the utility of Tregs for T1DM in humans was provided by a study of pediatric patients with new onset T1DM. After 12 months of follow-up, about 66 percent of children treated were in remission, compared to only 20 percent of concurrent controls, and two Treg treated children achieved complete insulin independence, while none of the control children achieved this endpoint. Initiation of Phase 2 study is expected for Q3.

    Sentiment: Strong Buy

  • Reply to

    Pump Monkey's will lose it all !!!

    by duwainjackson Jun 15, 2014 12:04 AM
    neii neii Jun 15, 2014 5:30 PM Flag

    Every man loses it after a pump monkey event....it doesn't mean there isn't a tomorrow!

    Sentiment: Strong Buy

  • Reply to

    Bullish Inverted Labia Chartparttern Noted

    by neii Jun 13, 2014 6:40 PM
    neii neii Jun 14, 2014 11:18 AM Flag

    Very rare that these two patterns juxtapose.......bullish outcomes indeed!!

    Sentiment: Strong Buy

  • Stay Long!

    Sentiment: Strong Buy

  • Reply to

    6 6 6

    by neii Apr 10, 2014 4:55 PM
    neii neii Apr 16, 2014 4:56 PM Flag

    IT'S HERE!!!!

NBS
6.10+0.09(+1.50%)12:36 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.